CoChat
Sign Up
Cited by 119Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and TreatmentsDrug Transport and Resistance Mechanisms

The DOI matches its Crossref record; 31 of the 33 references it cites were found in a registry or an index.

Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis

Leuschner, Maria, Güldütuna, Sükrettin, You, Tiangeng, Hübner, Klaus, Bhatti, Susan, Leuschner, Ulrich·1996·Journal of Hepatology
DOI 10.1016/s0168-8278(96)80327-8
Open this paper in CoChat — free account

Abstract

Background Ursodeoxycholic acid probably is not able to cure primary biliary cirrhosis. Therefore in this study ursodeoxycholic acid was administered together with prednisolone, since monotherapy with glucocorticoids has been shown to have some positive effects. Methods Thirty patients with primary biliary cirrhosis (stages I-III) were entered into the study. Fifteen were treated with ursodeoxycholic acid 10 mg.kg-1.day-1 and placebo (group A), 15 with ursodeoxycholic acid and 10 mg prednisolone (group B) for 9 months. Apart from the usual laboratory examinations, liver biopsies were taken from 29 patients before and after therapy. Results Liver enzymes decreased significantly compared to the initial values in both groups (p < 0.001), but in group B cholestasis-indicating enzymes and the immunoglobulins G and A improved more rapidly. Between both groups the differences for AP, GGT, IgG, IgA and gamma-globulins were significant (p < 0.05), but only for short terms. In group B, liver histology improved significantly (p < 0.003), which correlated with the decrease of IgG. Ursodeoxycholic acid became the predominant bile acid in the serum. Toxic bile acids did not increase. Bone densitometry revealed a slight deterioration of preexisting osteoporosis in one patient. Conclusions Although combination therapy with ursodeoxycholic acid and prednisolone was not superior to monotherapy with ursodeoxycholic acid with regard to liver function tests, it had a highly beneficial influence on liver histology. In our previous trials with monotherapy histology remained unchanged. An early decrease in IgG during combination therapy seems to be an indicator of an amelioration of liver histology.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0168-8278(96)80327-8

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 3

  1. David, 1985, Die Wirkung von Ursodesoxycholsäure bei chronischen Leberkrankheiten, Eine Pilotstudie (abstr.). Z Gastroenterol, 23, 420
  2. Schaffner, 1991, Ursodeoxycholic acid (U) + colchicine (C) for treatment of primary biliary cirrhosis (PBC) (abstr.), Hepatology, 14, 62A
  3. Kaplan, 1992, The therapeutic effects of ursodiol and methotrexate are additive and well tolerated in primary biliary cirrhosis (abstr.), Hepatology, 16, 92A

Cited by

Sorted by citations

See all 119

Related

See all

Metadata

Authors
Leuschner, M., Güldütuna, S., You, T., Hübner, K., Bhatti, S., & Leuschner, U.
Affiliations
Goethe University Frankfurt (DE)
Corresponding author
Leuschner, Ulrich
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
1996-07
Volume
25
Issue
1
Pages
49-57
ISSN
0168-8278 (ISSN-L)
DOI
10.1016/s0168-8278(96)80327-8
OpenAlex
W2012146760
Cited by
119
References
33
Citations by year
2026: 1 · 2025: 3 · 2024: 3 · 2020: 2 · 2019: 4 · 2018: 1 · 2017: 5 · 2016: 3 · 2015: 5 · 2014: 6 · 2013: 1 · 2012: 5
FWCI
2.98
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Journal of Hepatology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
primary biliary cirrhosis, ursodeoxycholic acid, prednisolone, combination therapy, glucocorticoids, liver histopathology, IgG, cholestasis, serum bile acids, osteoporosis, early-stage disease
MeSH terms
Adult, Aged, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Immunoglobulin G, Liver, Liver Cirrhosis, Biliary, Male, Middle Aged, Prednisolone, Prospective Studies, Ursodeoxycholic Acid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review